|Articles|July 20, 2022
Supplements and Featured Publications
- Oncology Care Pathways Supporting the Use of High-value Treatments for NSCLC
Oncology Care Pathways Supporting the Use of High-value Treatments for NSCLC
Advertisement
This AJMC® publication explores the value of clinical oncology care pathways in non–small cell lung cancer (NSCLC) with insights from Edward Arrowsmith, MD, Medical Director for Pathways at OneOncology in Chattanooga, Tennessee.
Newsletter
Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on AJMC
1
FDA Approves Inebilizumab for Generalized Myasthenia Gravis
2
Clascoterone 5% Delivers Strong Phase 3 Results for Androgenetic Alopecia
3
Cardiotoxicity Remains a Concern as Breast Cancer Survival Rates Improve: Eric H. Yang, MD
4
5 Key Oncology FDA Approvals From November
5





































